RenovoRx Management
Management criteria checks 1/4
RenovoRx's CEO is Shaun Bagai, appointed in Jun 2014, has a tenure of 12.08 years. total yearly compensation is $1.23M, comprised of 47.3% salary and 52.7% bonuses, including company stock and options. directly owns 0.81% of the company’s shares, worth $327.90K. The average tenure of the management team and the board of directors is 1.9 years and 8 years respectively.
Key information
Shaun Bagai
Chief executive officer
US$1.2m
Total compensation
| CEO salary percentage | 47.35% |
| CEO tenure | 12.1yrs |
| CEO ownership | 0.8% |
| Management average tenure | 1.9yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
RNXT: Phase III Pancreatic Cancer Data And New Patent Portfolio Will Drive Upside
Analysts have updated their price target on RenovoRx stock from $5.56 to $7.03, citing revisions to fair value assumptions, discount rate, expected revenue growth, profit margin outlook, and future P/E estimates. What's in the News for RenovoRx RenovoRx reported publication of a peer reviewed case study from Moffitt Cancer Center in Radiology Case Reports, describing use of its TAMP procedure and RenovoCath device to deliver intra arterial gemcitabine in locally advanced pancreatic cancer, with PET CT showing a 52% reduction in tumor metabolic activity at 4 month follow up.Here's Why We're Watching RenovoRx's (NASDAQ:RNXT) Cash Burn Situation
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...RenovoRx (NASDAQ:RNXT) Is Revolutionizing Cancer Treatment
RenovoRx, Inc. (Nasdaq: RNXT), based in Mountain View, California, is a clinical-stage biopharma company taking a new approach to cancer treatment. Using its Trans-Arterial Micro-Perfusion (TAMP™) platform, the company aims to solve a major issue in cancer care: how to get strong doses of chemo directly to the tumor while avoiding harmful side effects throughout the body.Revolutionizing Cancer Treatment
A small incision is made in the leg to insert the RenovoCath® system.RenovoRx: From Clinical Promise To Commercial Reality And Trading At A Significant Discount
Summary RenovoRx's innovative RenovoCath and TAMP platform show promising clinical data, extending pancreatic cancer survival rate 5 months and improving quality of life. The company’s market cap of $70M is undervalued compared to an intrinsic value of $243M, driven by early commercial traction and strategic partnerships. Leadership and advisory board bring extensive experience, enhancing RenovoRx's potential for successful commercialization and market expansion. Positive clinical data, physician demand, and a new reimbursement code accelerated RenovoCath sales by an estimated 2 years. Read the full article on Seeking AlphaWe Think RenovoRx (NASDAQ:RNXT) Needs To Drive Business Growth Carefully
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is RenovoRx (NASDAQ:RNXT) In A Good Position To Invest In Growth?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Companies Like RenovoRx (NASDAQ:RNXT) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although...RenovoRx reports Q2 results
RenovoRx press release (NASDAQ:RNXT): Q2 Net Loss of $2.6M As of June 30, 2022, the company had cash and cash equivalents and short-term marketable securities of $10.8M.Is RenovoRx (NASDAQ:RNXT) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...RenovoRx names new finance CFO
RenovoRx (NASDAQ:RNXT) appoints James Ahlers as CFO, effective July 15, 2022, and the addition of Ronald B. Kocak as VP and Controller. Mr. Ahlers replaces Christopher J. Lehman, who joined in connection with its IPO and is leaving to pursue a new business opportunity. Mr. Ahlers served as CFO of Intarcia Therapeutics and has held senior finance roles with Titan Pharmaceuticals and Ansan Pharmaceuticals.RenovoRx (NASDAQ:RNXT) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...We Think RenovoRx (NASDAQ:RNXT) Can Afford To Drive Business Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although...CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$12m |
| Dec 31 2025 | US$1m | US$583k | -US$11m |
| Sep 30 2025 | n/a | n/a | -US$11m |
| Jun 30 2025 | n/a | n/a | -US$11m |
| Mar 31 2025 | n/a | n/a | -US$10m |
| Dec 31 2024 | US$1m | US$520k | -US$9m |
| Sep 30 2024 | n/a | n/a | -US$9m |
| Jun 30 2024 | n/a | n/a | -US$8m |
| Mar 31 2024 | n/a | n/a | -US$8m |
| Dec 31 2023 | US$939k | US$520k | -US$10m |
| Sep 30 2023 | n/a | n/a | -US$9m |
| Jun 30 2023 | n/a | n/a | -US$10m |
| Mar 31 2023 | n/a | n/a | -US$10m |
| Dec 31 2022 | US$841k | US$495k | -US$10m |
| Sep 30 2022 | n/a | n/a | -US$10m |
| Jun 30 2022 | n/a | n/a | -US$9m |
| Mar 31 2022 | n/a | n/a | -US$8m |
| Dec 31 2021 | US$988k | US$323k | -US$6m |
| Sep 30 2021 | n/a | n/a | -US$5m |
| Jun 30 2021 | n/a | n/a | -US$4m |
| Mar 31 2021 | n/a | n/a | -US$4m |
| Dec 31 2020 | US$253k | US$253k | -US$4m |
| Dec 31 2019 | US$270k | US$240k | -US$4m |
Compensation vs Market: Shaun's total compensation ($USD1.23M) is above average for companies of similar size in the US market ($USD658.00K).
Compensation vs Earnings: Shaun's compensation has increased whilst the company is unprofitable.
CEO
Shaun Bagai (49 yo)
Mr. Shaun R. Bagai has been the Chief Executive Officer and Director of RenovoRx, Inc. since June 2014. He is Secretary at RenovoRx, Inc. He joined RenovoRx in June 2014 and in his first few months has bee...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.2yrs | US$692.25k | 1.77% $ 718.6k | |
| CEO, Secretary & Director | 12.1yrs | US$1.23m | 0.81% $ 327.9k | |
| VP of Finance & Controller | 4.8yrs | US$616.70k | 0.028% $ 11.3k | |
| CFO & Principal Accounting Officer | less than a year | no data | 0.42% $ 170.5k | |
| Vice President of Operations and R&D | 1.7yrs | no data | no data | |
| Chief Clinical Officer | no data | US$890.15k | 0% $ 0 | |
| Senior VP and Head of Corporate Strategy & Partnerships | 2.1yrs | no data | no data |
Experienced Management: RNXT's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 8.2yrs | US$692.25k | 1.77% $ 718.6k | |
| CEO, Secretary & Director | 12.1yrs | US$1.23m | 0.81% $ 327.9k | |
| Independent Director | 13.5yrs | US$117.89k | 0% $ 0 | |
| Independent Director | 13.6yrs | US$105.39k | 0.17% $ 68.3k | |
| Member of Scientific Advisory Board | 3.1yrs | no data | no data | |
| Independent Director | 3.3yrs | US$105.39k | 0.091% $ 36.9k | |
| Independent Director | 7.8yrs | US$107.89k | 0.091% $ 36.9k | |
| Member of Scientific Advisory Board | less than a year | no data | no data | |
| Member of Advisory Board | 9yrs | no data | no data | |
| Member of Advisory Board | 9yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.7yrs | no data | no data | |
| Member of Medical Advisory Board | less than a year | no data | no data |
Experienced Board: RNXT's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/09 04:24 |
| End of Day Share Price | 2026/07/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
RenovoRx, Inc. is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| Edward Woo | Ascendiant Capital Markets LLC |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |